PDEPT: polymer-directed enzyme prodrug therapy

Polymer-directed enzyme prodrug therapy (PDEPT) is a novel two-step antitumour approach using a combination of a polymeric prodrug and polymer-enzyme conjugate to generate cytotoxic drug selectively at the tumour site. In this study the polymeric prodrug N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-Gly-Phe-Leu-Gly-doxorubicin conjugate PK1 (currently under Phase II clinical evaluation) was selected as the model prodrug, and HPMA copolymer-cathepsin B as a model for the activating enzyme conjugate. Following polymer conjugation (yield of 30–35%) HPMA copolymer-cathepsin B retained ~20–25% enzymatic activity in vitro. To investigate pharmacokinetics in vivo, 125I-labelled HPMA copolymer-cathepsin B was administered intravenously (i.v.) to B16F10 tumour-bearing mice. HPMA copolymer-cathespin B exhibited a longer plasma half-life (free cathepsin B t1/2α = 2.8 h; bound cathepsin B t1/2α = 3.2 h) and a 4.2-fold increase in tumour accumulation compared to the free enzyme. When PK1 (10 mg kg–1 dox-equiv.) was injected i.v. into C57 mice bearing subcutaneously (s.c.) palpable B16F10 tumours followed after 5 h by HPMA copolymer-cathepsin B there was a rapid increase in the rate of dox release within the tumour (3.6-fold increase in the AUC compared to that seen for PK1 alone). When PK1 and the PDEPT combination were used to treat established B16F10 melanoma tumour (single dose; 10 mg kg–1 dox-equiv.), the antitumour activity (T/C%) seen for the combination PDEPT was 168% compared to 152% seen for PK1 alone, and 144% for free dox. Also, the PDEPT combination showed activity against a COR-L23 xenograft whereas PK1 did not. PDEPT has certain advantages compared to ADEPT and GDEPT. The relatively short plasma residence time of the polymeric prodrug allows subsequent administration of polymer-enzyme without fear of prodrug activation in the circulation and polymer-enzyme conjugates have reduced immunogenicity. This study proves the concept of PDEPT and further optimisation is warranted. © 2001 Cancer Research Campaign http://www.bjcancer.com

[1]  Duncan,et al.  Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? , 1999, Pharmaceutical science & technology today.

[2]  C. Conover,et al.  Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. , 1998, Anti-cancer drug design.

[3]  Young,et al.  Gene directed enzyme prodrug therapy for cancer. , 1997, Advanced drug delivery reviews.

[4]  C. Springer,et al.  Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs , 1996 .

[5]  A. Photiou,et al.  Antibody-directed enzyme prodrug therapy (ADEPT). , 1996, International journal of oncology.

[6]  T. A. Connors.  Is there a future for cancer chemotherapy? The Michel Clavel Lecture. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Connors Ta.  The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. , 1995 .

[8]  S. Sharma,et al.  Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  K. Ulbrich,et al.  Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. , 1994, British Journal of Cancer.

[10]  H. Svensson,et al.  Synthesis and characterization of monoclonal antibody-beta-lactamase conjugates. , 1994, Bioconjugate chemistry.

[11]  R. Duncan,et al.  Drug-polymer conjugates: potential for improved chemotherapy. , 1992, Anti-cancer drugs.

[12]  C. Springer,et al.  Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. , 1991, European journal of cancer.

[13]  S. Skinner,et al.  Microvascular architecture of experimental colon tumors in the rat. , 1990, Cancer research.

[14]  V. Šubr,et al.  Immunogenicity of Protein-N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates in A/J and B10 Mice , 1990 .

[15]  K. Ulbrich,et al.  The pharmacokinetics of polymer-bound adriamycin. , 1990, Biochemical pharmacology.

[16]  K. Ulbrich,et al.  Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. , 1989, Biomaterials.

[17]  H. Dvorak,et al.  Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.

[18]  K. D. Bagshawe,et al.  Antibody directed enzymes revive anti-cancer prodrugs concept. , 1987, British Journal of Cancer.

[19]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[20]  M. Keating,et al.  Clinical pharmacology of polyethylene glycol-L-asparaginase. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[21]  N. Bleehen,et al.  Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). , 1985, British Journal of Cancer.

[22]  J. Kopeček,et al.  Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes† , 1983 .

[23]  Y. Ashihara,et al.  Modification of E. coli L-asparaginase with polyethylene glycol: disappearance of binding ability to anti-asparaginase serum. , 1978, Biochemical and biophysical research communications.

[24]  F M Muggia,et al.  Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  L. Murray,et al.  Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  D. Brewster,et al.  Trends in cancer incidence and mortality in Scotland: description and possible explanations. , 1998, British Journal of Cancer.

[27]  N. J. McNally,et al.  United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). , 1998, British Journal of Cancer.

[28]  K. Ulbrich,et al.  Polymeric conjugates of drugs and antibodies for site‐specific drug delivery , 1996 .

[29]  T. A. Connors.  The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. , 1995, Gene therapy.

[30]  Z. Ram,et al.  In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. , 1993, Cancer research.

[31]  C Delgado,et al.  The uses and properties of PEG-linked proteins. , 1992, Critical reviews in therapeutic drug carrier systems.

[32]  G. Dreyer,et al.  The Blood Volume of Mammals as Determined by Experiments upon Rabbits, Guinea-Pigs, and Mice; and Its Relationship to the Body Weight and to the Surface Area Expressed in a Formula , 1911 .